Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CONCORD DRUGS vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CONCORD DRUGS   ACTAVIS
EQUITY SHARE DATA
    CONCORD DRUGS
Mar-23
ACTAVIS
Dec-18
CONCORD DRUGS/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs4216,159-   
Low Rs2010,840-   
Sales per share (Unadj.) Rs55.93,963.8-  
Earnings per share (Unadj.) Rs1.1-1,276.8-  
Cash flow per share (Unadj.) Rs2.8417.7-  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs33.416,349.0-  
Shares outstanding (eoy) m9.32332.60-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.53.4 16.1%   
Avg P/E ratio x28.9-10.6 -273.3%  
P/CF ratio (eoy) x10.932.3 33.8%  
Price / Book Value ratio x0.90.8 110.8%  
Dividend payout %00-   
Avg Mkt Cap Rs m2854,489,898 0.0%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m380-   
Avg. sales/employee Rs Th078,010.2-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0-25,127.1-  
INCOME DATA
Net Sales Rs m5211,318,372 0.0%  
Other income Rs m025,212 0.0%   
Total revenues Rs m5211,343,584 0.0%   
Gross profit Rs m4634,548 0.1%  
Depreciation Rs m16563,576 0.0%   
Interest Rs m1776,078 0.0%   
Profit before tax Rs m12-579,893 -0.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0147,896 0.0%   
Tax Rs m3-7,349 -0.0%   
Profit after tax Rs m10-424,648 -0.0%  
Gross profit margin %8.82.6 335.0%  
Effective tax rate %21.11.3 1,664.1%   
Net profit margin %1.9-32.2 -5.9%  
BALANCE SHEET DATA
Current assets Rs m435540,727 0.1%   
Current liabilities Rs m216478,345 0.0%   
Net working cap to sales %41.94.7 886.3%  
Current ratio x2.01.1 177.9%  
Inventory Days Days720 33.3%  
Debtors Days Days1,10866 1,671.0%  
Net fixed assets Rs m148149,232 0.1%   
Share capital Rs m930-   
"Free" reserves Rs m2180-   
Net worth Rs m3115,437,670 0.0%   
Long term debt Rs m191,914,801 0.0%   
Total assets Rs m5828,500,316 0.0%  
Interest coverage x1.7-6.6 -26.2%   
Debt to equity ratio x0.10.4 17.4%  
Sales to assets ratio x0.90.2 576.7%   
Return on assets %4.6-4.1 -112.7%  
Return on equity %3.2-7.8 -40.5%  
Return on capital %8.9-4.8 -184.7%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m00-   
CASH FLOW
From Operations Rs m17471,005 0.0%  
From Investments Rs m-23258,756 -0.0%  
From Financial Activity Rs m6-808,385 -0.0%  
Net Cashflow Rs m0-78,232 -0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 83.51 Rs / USD

Compare CONCORD DRUGS With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare CONCORD DRUGS With: HESTER BIOSCIENCES  CHEMO PHARMA  ASTRAZENECA PHARMA  ERIS LIFESCIENCES  LACTOSE INDIA  



Today's Market

Sensex Today Ends 456 Points Lower | IT Stocks Drag | 5 Reasons Why Indian Share Market is Falling Sensex Today Ends 456 Points Lower | IT Stocks Drag | 5 Reasons Why Indian Share Market is Falling(Closing)

After opening the negative note, Indian share markets Slipped further as the session progressed and ended the day weak.